Brain Activity Effects of Psychedelic Medicines in Healthy Volunteers

Non-randomised, open-label study in healthy volunteers testing single oral doses of psilocybin (25–35 mg by weight tiers) or MDMA (80 mg with optional 40 mg booster); some participants may return ≥3 months later to receive the alternate drug.

Primary outcomes include EEG measures (N100 in a latent inhibition task and power-frequency slope of non-oscillatory activity) assessed at baseline (within 16 days pre-dose) and once post-dose (within 16 days post-dose).